In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 (2021)
Attributed to:
New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkab072
PubMed Identifier: 33880524
Publication URI: http://europepmc.org/abstract/MED/33880524
Type: Journal Article/Review
Parent Publication: Journal of Antimicrobial Chemotherapy
Issue: 7
ISSN: 0305-7453